USA |NASDAQ |USD
Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
---|---|---|---|---|
Aug 11, 2022 | Jun 2022 | $-0.68 | - | $-0.75 |
Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
---|---|---|---|---|
Aug 11, 2022 | Jun 2022 | $860.00K | - | $761.00K |
Ayala Pharmaceuticals, Inc's next earnings date is Thursday, Aug 11, 2022 for the fiscal quarter ending Jun 2022.
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Jun 2022 | 6 | $-0.68 | $-0.77 | $-0.56 |
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 7 | $-2.37 | $-2.83 | $-1.58 |
Dec 2023 | 7 | $-2.08 | $-3.54 | $-0.48 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Jun 2022 | 1 / 2 | $-0.66 | $-0.66 | $-0.66 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Dec 2022 | 5 / 0 | $-2.59 | $-2.45 | $-2.45 |
Dec 2023 | 4 / 1 | $-2.28 | $-2.29 | $-2.29 |
Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
---|---|---|---|---|
Jun 2022 | 6 | $860.00K | $700.00K | $1.10M |
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 7 | $3.19M | $2.20M | $4.00M |
Dec 2023 | 8 | $3.25M | $0.00 | $9.00M |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
May 12, 2022 | Mar 2022 | $-0.68 | - | - |
Mar 28, 2022 | Dec 2021 | $-0.61 | $-0.66 | -8.20% |
Nov 15, 2021 | Sep 2021 | $-0.80 | $-0.68 | 14.73% |
Aug 12, 2021 | Jun 2021 | $-0.62 | $-0.75 | -20.97% |
May 14, 2021 | Mar 2021 | $-0.64 | $-0.74 | -16.54% |
Mar 24, 2021 | Dec 2020 | $-0.58 | $-0.73 | -25.15% |
Nov 16, 2020 | Sep 2020 | $-0.55 | $-0.59 | -8.18% |
Aug 12, 2020 | Jun 2020 | $-0.51 | $-0.74 | -44.47% |
Jun 22, 2020 | Mar 2020 | $-0.61 | $-1.32 | -117.46% |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Mar 28, 2022 | Dec 2021 | $-2.75 | $-2.83 | - |
Mar 24, 2021 | Dec 2020 | $-3.12 | $-3.38 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
May 12, 2022 | Mar 2022 | $830.00K | - | - |
Mar 28, 2022 | Dec 2021 | $690.00K | $1.15M | 1.66% |
Nov 15, 2021 | Sep 2021 | $840.00K | $625.00K | 0.74% |
Aug 12, 2021 | Jun 2021 | $1.02M | $761.00K | 0.75% |
May 14, 2021 | Mar 2021 | $1.30M | $974.00K | 0.75% |
Mar 24, 2021 | Dec 2020 | $1.00M | $1.00M | 1.00% |
Nov 16, 2020 | Sep 2020 | $0.00 | $658.00K | - |
Aug 12, 2020 | Jun 2020 | $420.00K | $1.04M | 2.49% |
Jun 22, 2020 | Mar 2020 | $280.00K | $1.00M | 3.58% |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Mar 28, 2022 | Dec 2021 | $3.03M | $3.51M | 15.71% |
Mar 24, 2021 | Dec 2020 | $3.71M | $3.71M | 0.00% |
AYLA's next earnings date is Thursday, Aug 11, 2022 for the fiscal quarter ending Jun 30, 2022.
According to analysts, the average EPS estimation for Ayala Pharmaceuticals, Inc's next quarterly earnings is $-0.68, with a low EPS estimation of $-0.77, and a high estimation of $-0.56.
Over the last 1 month, EPS estimates have seen 1 upward revisions and 2 downward. The EPS 1 month trend is $-0.66, the last 2 month trend is $-0.66, and the 3 month trend is $-0.66.
Based on analysts, the average revenue estimation is $860.00K, with a low revenue estimation of $700.00K, and a high estimation of $1.10M.
Ayala Pharmaceuticals, Inc's previous earnings date was May 12, 2022 for its fiscal quarter ended Mar 31, 2022.
Ayala Pharmaceuticals, Inc's previous annual earnings date was Mar 28, 2022 for its fiscal year ended Dec 31, 2021.
AYLA's earnings per share (EPS) was $-2.83, missing the consensus analysts forecast of $-2.75 by 2.91% , and higher than the previous year's EPS (Dec 2020) by -16.27%.
Revenues were $3.51M, better than the forecast of $3.03M by 15.71%, and down by -5.45% from previous year's revenue.
The company reported a net income of $-40.25M.
Ayala Pharmaceuticals, Inc reported a free cash flow of $-38.36M for its fiscal year, compared to $-27.59M a year ago.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.